Cargando…
First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American College of Chest Physicians. Published by Elsevier Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640891/ https://www.ncbi.nlm.nih.gov/pubmed/33160536 http://dx.doi.org/10.1016/j.chest.2020.06.052 |
| _version_ | 1783605840384622592 |
|---|---|
| author | Mastroianni, Fiore |
| author_facet | Mastroianni, Fiore |
| author_sort | Mastroianni, Fiore |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7640891 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | American College of Chest Physicians. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76408912020-11-05 First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19 Mastroianni, Fiore Chest Correspondence American College of Chest Physicians. Published by Elsevier Inc. 2020-11 2020-11-04 /pmc/articles/PMC7640891/ /pubmed/33160536 http://dx.doi.org/10.1016/j.chest.2020.06.052 Text en © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Mastroianni, Fiore First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19 |
| title | First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19 |
| title_full | First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19 |
| title_fullStr | First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19 |
| title_full_unstemmed | First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19 |
| title_short | First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19 |
| title_sort | first, do no harm: caution against use of tocilizumab in covid-19 |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640891/ https://www.ncbi.nlm.nih.gov/pubmed/33160536 http://dx.doi.org/10.1016/j.chest.2020.06.052 |
| work_keys_str_mv | AT mastroiannifiore firstdonoharmcautionagainstuseoftocilizumabincovid19 |